Diagnostic Potential of Periostin, Galectin-3 and Tenascin C Serum Measurements in Inflammatory Bowel Disease: Pilot Study

TL;DR

This pilot study explores the potential of three proteins in blood as biomarkers for diagnosing and monitoring inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.

Contribution

The study identifies periostin and galectin-3 as promising serum biomarkers for IBD diagnosis and treatment monitoring.

Findings

Periostin showed excellent accuracy in differentiating UC and CD patients from healthy individuals.

Galectin-3 levels correlated with CRP in CD and changed with treatment in both UC and CD patients.

Periostin and galectin-3 levels decreased significantly in CD patients after conventional anti-inflammatory treatment.

Abstract

Inflammatory bowel diseases (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), are characterized by a complex interplay between chronic inflammatory process and extracellular matrix (ECM) remodeling. This pilot study aims to evaluate the serum levels of three ECM-related proteins—periostin, galectin-3, and tenascin C—as biomarkers supporting IBD diagnosis. Serum concentration of periostin, galectin-3 and tenascin C were measured using the ELISA method in 49 patients with IBD and 30 healthy individuals. Periostin and galectin-3 levels differed significantly between IBD patients and healthy individuals, whereas tenascin C levels did not show a significant difference. The ROC curve analysis identified periostin as the most promising biomarker for differentiation of both UC and CD from healthy individuals. In UC patients, periostin distinguished them from healthy individuals with excellent accuracy (AUC = 0.922), high sensitivity (100%), and good specificity (77.8%). Similarly, in CD patients, periostin demonstrated excellent diagnostic performance with AUC of 0.943, high sensitivity (100%) and good specificity (77.8%). Galectin-3 also showed potential as a diagnostic marker, which discriminated both UC and CD patients with high accuracy of AUC = 0.745 in UC and AUC = 0.691 in CD groups. Moreover, serum galectin-3 levels correlated with CRP levels (r = 0.603, p < 0.05) in the CD group. After one year of conventional anti-inflammatory treatment in CD patients, levels of periostin (p < 0.001) and galectin-3 (p < 0.05) significantly decreased. In contrast UC patients, receiving anti-TNF-α biological therapy showed a significant increase in galectin-3 (p < 0.05) concentrations. Obtained results indicate that circulating periostin and galectin-3 emerge as promising biomarkers for differentiating both UC and CD patients from healthy individuals. Given the significant correlation between galectin-3 and CRP serum levels, galectin-3 may also serve as a useful marker for monitoring disease activity in CD. Furthermore, galectin-3 may be helpful in monitoring the response to both biological or conventional anti-inflammatory treatment in UC and CD patients. Periostin, in turn, may be particularly valuable for evaluating efficacy of conventional anti-inflammatory therapy in CD.

Figures